Share on StockTwits

Smith & Nephew plc (NYSE:SNN)‘s stock had its “neutral” rating reiterated by stock analysts at Credit Suisse in a report issued on Monday.

A number of other analysts have also recently weighed in on SNN. Analysts at Berenberg Bank reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Monday. Separately, analysts at Beaufort Securities downgraded shares of Smith & Nephew plc to a “hold” rating in a research note on Monday. Finally, analysts at Investec downgraded shares of Smith & Nephew plc to a “buy” rating in a research note on Friday. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $97.00.

Shares of Smith & Nephew plc (NYSE:SNN) traded up 0.10% on Monday, hitting $89.50. 138,154 shares of the company’s stock traded hands. Smith & Nephew plc has a one year low of $57.99 and a one year high of $100.90. The stock has a 50-day moving average of $89.2 and a 200-day moving average of $80.81. The company has a market cap of $16.003 billion and a P/E ratio of 30.78.

Smith & Nephew plc (NYSE:SNN) last announced its earnings results on Friday, August 1st. The company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.08. On average, analysts predict that Smith & Nephew plc will post $4.14 earnings per share for the current fiscal year.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (NYSE:SNN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.